Developing an In-vitro Diagnostic Risk-Stratification Test for Oral Cancer

Status Recruiting

Clinical Trial Summary

The purpose of this study is to verify the discriminatory value of previously identified salivary transcriptome and proteome markers for oral squamous cell cancer in an intended use population of patients with oral lesions suspicious for cancer.

Clinical Trial Description

Saliva samples are collected from patients before clinically driven oral biopsy for lesions suspicious for cancer. Specimens are processed by laboratory personnel blinded to the tissue diagnosis. Six pre-specified mRNA markers (IL1b, IL8, SAT, DUSP1, OAZ1 and S100P) are measured by polymerase chain reaction. Markers are compared in cancer and control by raw Ct values as well as by delta Ct after adjustment for housekeeping gens. Appropriate housekeeping genes are identified in a random subset of cancer and control patients and then verified in the remaining subjects. Predictive models are generated by a pre-specified method and robustness evaluated by bootstrap analysis. The model is then further validated in a second cohort. Three pre-specified protein markers (IL8, IL1B, and M2BP) are a secondary endpoint and will also be compared in cancer and control patients. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01587573
Study type	Observational
Source	PeriRx
Contact
Status	Recruiting
Phase
Start date	April 2012
Completion date	December 2018

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04543266` - Predicting Metastatic Oral Squamous Cell Carcinomas With Molecular Biomarkers Using Machine Learning
Not yet recruiting	`NCT06438939` - NBI for Early Diagnosis of OPMD/OSCC	N/A
Recruiting	`NCT05024383` - Dissecting the Heterogeneity of Oral Cancer Pain	N/A
Recruiting	`NCT06031337` - Salivary Expression of SOX7 in Oral Squamous Cell Carcinoma: Diagnostic Accuracy Study
Not yet recruiting	`NCT06174428` - Validity of Viome's Oral/Throat Cancer Test
Recruiting	`NCT05098119` - Neoadjuvant Sintilimab Combined With Reduction of Cycles of Chemotherapy in Resectable Oral Cavity or Oropharyngeal Squamous Cell Carcinoma (OOC-002)	Phase 2
Recruiting	`NCT05069857` - Neoadjuvant Personalized Anti-PD-1 and Anti-VEGFR Therapy in OSCC Patients	Phase 2
Not yet recruiting	`NCT03619304` - Assessment of Anti-cancerous Effect of Green, Roasted and Decaffeinated Coffee on Oral Squamous Cell Carcinoma Cell Line	N/A
Active, not recruiting	`NCT01772706` - Laser Mucite ORL : Effectiveness of Laser Therapy for Mucositis Induced by a Radio-chemotherapy in Head and Neck Cancer	N/A
Recruiting	`NCT05893888` - Safety and Efficacy Study of PRV211 in Subjects With Oral Squamous Cell Carcinoma	Phase 1/Phase 2
Recruiting	`NCT05125055` - Neoadjuvant Anti-PD-1 and TP Versus TPF on Pathological Response in OSCC	Phase 2/Phase 3
Not yet recruiting	`NCT06055868` - People Living With HIV, Oral and Oropharyngeal Cancer, and Health Equity
Not yet recruiting	`NCT06130007` - A Prospective, Single-arm Phase II Clinical Trial of Tislelizumab Combined With Platinum Doublet Neoadjuvant Therapy to Improve Mandibular Preservation in Resectable Locally Advanced Oral Squamous Cell Carcinoma.	Phase 2
Recruiting	`NCT05798793` - Neoadjuvant Anti-PD-1 Immunotherapy With Chemotherapy in Resectable Locally Advanced Oral Squamous Cell Carcinoma	Phase 3
Recruiting	`NCT02739204` - Concurrent Radiotherapy and/or Cisplatin With or Without Celecoxib in Patients With Primary Oral Squamous Cell Carcinoma	Phase 2
Completed	`NCT05708209` - The Long Non Coding MALAT1 as a Potential Salivary Diagnostic Biomarker in Oral Squamous Cell Carcinoma Through Targeting mi RNA 124
Recruiting	`NCT05862168` - Neoadjuvant Treatment of Tislelizumab Combined Chemotherapy for Locally Advanced Oral Squamous Cell Carcinoma ：A Single-arm, Prospective, Phase II Trial	Phase 2
Recruiting	`NCT05451303` - Detection of Oral and Throat Cancers Using OralViome Cancer Testing System
Recruiting	`NCT05902455` - Differential Mobility Spectrometry (DMS) Based Oral Tumor Analysis
Not yet recruiting	`NCT05803915` - Neoadjuvant Toripalimab Plus Nimotuzumab in Oral Squamous Cell Carcinoma Prior to Radical Therapy	Phase 2